Sign inJoin waitlistJoin the waitlist

Ashish Sangal

Chief of Medical Oncology & Hematology & Director of Clinical Research & Thoracic Oncology · Catholic Health

Credentials: · · · · ·

History

Medical Oncology & Hematology & Director of Clinical Research & Thoracic Oncology Division · Catholic Health
Present

Hematology and Medical Oncology
One Brooklyn Health System-Brookdale University Hospital Medical Center
2007–2010
Internal Medicine
One Brooklyn Health System-Brookdale University Hospital Medical Center
2002–2005
Coimbatore Medical College
1996–2000

Research

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in…
Journal for ImmunoTherapy of Cancer · 2021 · 144 citations
Thrombocytopenia in septic shock patients--a prospective observational study of incidence, risk factors and correlation with clinical outcome
Anaesthesia and Intensive Care · 2007 · 123 citations
Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
Clinical Cancer Research · 2017 · 122 citations

Johnny Kao
6 papers
GW
Glen Weiss
5 papers
Symeon Missios
3 papers
VK
Vivek Khemka
3 papers
EC
Emily Copel
2 papers
RR
Rachel Radigan
2 papers
Adrienne Victor
1 paper
Alexa Finkelstein
1 paper
Alissa Marr
1 paper
Anu Gaba
1 paper
AS
Anurag Singh
1 paper
Benjamin Powers
1 paper

Clinical trials

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Principal investigator · Terminated · Phase 1, Phase 2
Western Regional Medical Center
2014–2018
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Site PI · Recruiting
SWOG Cancer Research Network
2021–2028
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2026
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027